{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T22:36:02Z","timestamp":1785796562441,"version":"3.56.0"},"reference-count":13,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.oret.2025.07.015","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T21:50:22Z","timestamp":1754430622000},"page":"152-164","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Randomized Trial of Biosimilar ABP 938 Compared with Reference Aflibercept in Adults with Neovascular Age-Related Macular Degeneration"],"prefix":"10.1016","volume":"10","author":[{"given":"Scott","family":"Friedman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolas","family":"London","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Hamouz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1gnes","family":"Ker\u00e9nyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andras","family":"Papp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"Pregun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Bautista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daidong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Grachev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Franklin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.oret.2025.07.015_bib1","unstructured":"US Food and Drug Administration, PAVBLU (aflibercept-ayyh) - United States prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761298s000lbl.pdf. Accessed May 14, 2025."},{"key":"10.1016\/j.oret.2025.07.015_bib2","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.gendis.2021.02.009","article-title":"Age-related macular degeneration: epidemiology, genetics, pathophysiology, diagnosis, and targeted therapy","volume":"9","author":"Deng","year":"2022","journal-title":"Genes Dis"},{"key":"10.1016\/j.oret.2025.07.015_bib3","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1159\/000517520","article-title":"Age-related macular degeneration: pathophysiology, management, and future perspectives","volume":"244","author":"Flores","year":"2021","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.oret.2025.07.015_bib4","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.ophtha.2012.10.036","article-title":"Clinical classification of age-related macular degeneration","volume":"120","author":"Ferris","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.07.015_bib5","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1007\/s00417-017-3647-4","article-title":"Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases","volume":"255","author":"Lanzetta","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.oret.2025.07.015_bib11","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1007\/s40123-024-00914-1","article-title":"Analytical and functional similarity of aflibercept biosimilar ABP 938 with aflibercept reference product","volume":"13","author":"Seo","year":"2024","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.oret.2025.07.015_bib12","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s40123-024-01043-5","article-title":"Nonclinical similarity of the biosimilar candidate ABP 938 with aflibercept reference product","volume":"14","author":"Seo","year":"2025","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.oret.2025.07.015_bib13","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.07.015_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2022.101160","article-title":"Endpoints for clinical trials in ophthalmology","volume":"97","author":"Schmetterer","year":"2023","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.oret.2025.07.015_bib15","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ophtha.2021.04.031","article-title":"Efficacy and safety of biosimilar FYB201 compared with ranibizumab in neovascular age-related macular degeneration","volume":"129","author":"Holz","year":"2022","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.07.015_bib16","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1001\/jamaophthalmol.2020.5053","article-title":"Efficacy and safety of a proposed ranibizumab biosimilar product vs a reference ranibizumab product for patients with neovascular age-related macular degeneration: a randomized clinical trial","volume":"139","author":"Woo","year":"2021","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2025.07.015_bib17","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1001\/jamaophthalmol.2023.2260","article-title":"Efficacy and safety of the aflibercept biosimilar SB15 in neovascular age-related macular degeneration: a phase 3 randomized clinical trial","volume":"141","author":"Woo","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2025.07.015_bib18","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s40942-015-0005-8","article-title":"A review of optical coherence tomography angiography (OCTA)","volume":"1","author":"de Carlo","year":"2015","journal-title":"Int J Retina Vitreous"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653025003513?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653025003513?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T07:28:17Z","timestamp":1779866897000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468653025003513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2468653025003513"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2025.07.015","relation":{},"ISSN":["2468-6530"],"issn-type":[{"value":"2468-6530","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Randomized Trial of Biosimilar ABP 938 Compared with Reference Aflibercept in Adults with Neovascular Age-Related Macular Degeneration","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2025.07.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc. on behalf of American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}